As HLA‐A*01, HLA‐A*03 and HLA‐B*37 have each been associated with differential susceptibility to EBV+ lymphomas 15, 16, 17, 53, we aimed to increase the number of defined EBV latency antigen‐derived epitopes restricted by these HLA class I molecules. This evidence concerns the gene HLA-B and lymphoma.